FDA approved the first and only ready-to-use insulin for IV infusion in hospitals and acute care settings.
FDA approved the first and only ready-to-use insulin for IV infusion in hospitals and acute care settings.
Insulin Human in 0.9% Sodium Chloride Injection (Myxredlin, Baxter), which treats diabetes mellitus in both adult and pediatric patients, has an extended shelf life of 30 days at room temperature or 24 months if refrigerated in the original carton to protect from light, according to Baxter.
Related: Cybersecurity Glitch Wreaks Havoc On Insulin Pump
“Insulin is in the top 5 drug classes involved with medication errors, and more than 30 of those errors result in patient harm,” said Robert Felicelli, president of Pharmaceuticals at Baxter, in a press release from the company. “When a patient requires intravenous insulin in the hospital, pharmacists have to manually admix insulin for treatment. With the launch of Myxredlin, clinicians will have access to a convenient, reliable presentation of ready-to-use insulin that can help ensure faster delivery to patients, streamlined workflow for pharmacists and nurses, and less waste for hospitals."
Baxter expects the new IV insulin to be available by the end of the year
Related: Pharm Maker, PBMs Lower Insulin Prices
Myxredlin is provided in a standardized concentration of 100 units/100 ml in a flexible plastic container. “This innovative presentation helps ensure Myxredlin delivers a consistent, stable and predictable concentration with every administration, which is a key consideration for patient safety,” Baxter said.
Read more: Lack of Insulin Competition High Priority For FDA
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More